We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Most Drugmakers Keep Postmarket Promises But Are Slow to Update FDA
Most Drugmakers Keep Postmarket Promises But Are Slow to Update FDA
March 9, 2012
While most drugmakers are good about keeping postmarket clinical trials on schedule, they don’t always file their required annual status reports on time, so the FDA often isn’t up to date on their progress, the agency says.